News

NORD's Voice of the Community - February 2018

Takeda released new real-world data evaluating the comparative effectiveness of Entyvio (vedolizumab) and TNFα-antagonist in patients with moderately to severely active ulcerative colitis or Crohn’s disease.

Less invasive interventions could be achieved in AMD with encapsulated microspheres as a method of delivering treatment to patients.

Nativis, Inc. announced this morning that its Voyager Pediatric system has been granted a Humanitarian Use Designation from the U.S. FDA.

Roughly 41% of those diagnosed with psychiatric illness were also smokers, and they were 70% more likely to be smokers than their counterparts without psychiatric illness.

Among new users of LABA and LAMA, treatment was associated with a 1.50-fold and a 1.52-fold increase in CVD risk, respectively.

There has been only 1 study into the effect of viral eradication using interferon-based HCV therapy on the development of hepatic steatosis in patients with genotype 3 infection.

The tablet is a drug formulation of both immediate and extended release amantadine that provides once-daily therapy for adult patients.

Arrowhead Pharmaceuticals Inc. announced that the company’s second-generation investigational medicine ARO-AAT was granted orphan drug designation by the FDA.

The rate comes in spite of the fact that women are more likely to report more heart attack-associated symptoms, and to have been treated for such symptoms previously, than men.

Celgene Corporation announced that data from the Phase 3 RELIEF clinical trial of Otezla (apremilast) in patients with active Behçet’s disease with oral ulcers were presented.

Multiple Phase 3 studies that evaluated the treatment of Dysport in sustained spasticity patients will be presented at the annual meeting of the Association of Academic Physiatrists.

The chances of getting pregnant for current asthmatics who managed their symptoms with SABAs was 15% lower when compared to non-asthmatics.

Akcea announced that the Division of Metabolism and Endocrinology Products of the U.S. FDA will hold an advisory committee meeting to review data supporting the NDA for volanesorsen.

AstraZeneca and Merck announced that selumetinib, its MEK 1/2 inhibitor for the treatment of NF1, was granted orphan drug designation by the U.S. FDA.

Patients taking ustekinumab showed a 19% improvement in aortic inflammation compared to placebo.

Electronic medical records are driving docs crazy. Here’s why, and what’s being done to fix the problem, from the clinic to Congress.

A 20-year study of over 6000 European participants found reason to be concerned over the harm of cleaning chemicals.

The study suggests that postnatal depression is associated with increased risks to children’s development, affecting a range of domains.

Information sources such as healthcare professionals, social support and TV ads remain widely used for self-care.

There is some promising evidence for the use of microperimetry in functionally assessing AMD, despite research results being limited.

Tips for maximizing compliance based on 40 years of experience, and a new policy decision which could make matters worse.

While withdrawal of anticholinergic drugs has been investigated in the past to improve TD symptoms, evidence is weak for arguments in favor and against the drug class for TD.

When patients are given comprehensive education, have medications in hand, and have a follow-up appointment scheduled at discharge, they’re less likely to be readmitted to the hospital.

The CRL identified deficiencies related to the chemistry, manufacturing and control and flagged certain safety concerns about the concentration contained in the formula.

The first patients have been enrolled into the first-in-human IMM-529 clinical study for the treatment of Clostridium difficile infection.

Migraine was associated with a higher incidence of myocardial infarction, and ischaemic and haemorrhagic stroke.

The Stryker product is now cleared to be used up to 24 hours after symptom onset.

A newly released guideline for Canadian practitioners recommended against cannabinoids for most conditions, save for chronic neuropathic pain, chronic cancer-related pain, and refractory CINV and spasticity.

A new study finds tighter fuel standards for ships will have a major impact on public health globally.